Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Varicella Zoster Virus Downregulates Programmed Death & Promotes Inflammation

Lara C. Pullen, PhD  |  November 28, 2016

iStock_TestTubes_Generic_500x270The varicella zoster virus (VZV) can cause persistent inflammation and pathological vascular remodeling diagnosed as giant cell arteritis. VZV vasculopathy can also cause stroke and granulomatous aortitis. The pathologies develop when the virus reactivates from ganglia and spreads transaxonally to arterial adventitia.

Previous studies have shown that VZV infection causes the upregulation of programmed death ligand 1 (PD-L1) and the downregulation of major histocompatibility complex-1 (MHC-1). Scientists believe that both the virus-induced downregulation of MHC-1 and virus-induced dysregulation of PD-L1 are key to the persistence of the virus, but little is known about how VZV regulates PD-L1 expression.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dallas Jones, PhD, a post-doctoral fellow at the University of Colorado School of Medicine in Aurora, Colo., and colleagues described the results of their research on the role of PD-L1 in VZV vasculopathies online on Sept. 14 in the Journal of Virology.1 The team was surprised to discover that, when VZV infects human brain vascular adventitial fibroblasts and perineurial cells (both of which are adventitial cells), it downregulates expression of not only MHC-1, but also PD-L1. The same phenomenon also occurs when VZV infects human fetal lung fibroblasts. These findings were unexpected because previous studies have demonstrated that VZV infection upregulates PD-L1 in immune and non-immune cells.

When the investigators performed quantitative RT-PCR analyses, they found no change in PD-L1 transcript levels between mock- and VZV-infected cells. This result suggested that the downregulation occurred at the post-transcriptional level. The researchers discuss the implications in their paper: “We found that PD-L1 was downregulated in the VZV-infected vascular and lung cells, raising the possibility that apoptosis is not induced in infiltrating immune cells expressing PD-1. In addition, VZV-mediated downregulation of MHC-1 occurred prior to PD-L1 downregulation, potentially preventing presentation of viral antigens to these infiltrating immune cells. Taken together, the virus-induced dysregulation of PD-L1 and MHC-1 may contribute to ineffective viral clearance and persistent inflammation, which has been observed in virus-infected arteries of patients with VZV vasculopathy.” Thus, the persistent inflammation of vessels could lead to the pathological vascular remodeling that is characteristic of VZV vasculopathy. Likewise, persistent inflammation of infected lungs might promote subsequent infection of T cells followed by hematogenous virus spread.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Flow cytometry analyses revealed that, not only did VZV-infected cells have decreased expression of MHC-1 relative to mock-infected cells, but so did adjacent uninfected cells. This concurrent downregulation of MHC-1 in uninfected bystander cells occurred at 72 hours post-infection.

The researchers conclude, “Together, our studies provide a potential mechanism by which persistent inflammation in the absence of effective viral clearance occurs in VZV vasculopathy and VZV infection of the lung. Specifically, VZV-mediated downregulation of PD-L1 in vascular cells may contribute to the persistence of immune cells in VZV vasculopathy, which secrete soluble factors that produce loss of smooth muscle cells, a thickened intima and stroke.”

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsOther Rheumatic Conditions

Related Articles

    Varicella Zoster Virus May Cause Giant Cell Arteritis

    August 3, 2015

    Researchers have recently discovered a connection between the varicella zoster virus infection, which causes chicken pox and shingles, and giant cell arteritis…

    How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

    How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

    July 13, 2016

    The mechanistic link between human leukocyte antigen B27 (HLA-B27) and ankylosing spondylitis (AS) is one of the great enigmas in rheumatology. The introduction of biological therapies that target tumor necrosis factor (TNF) or the interleukin (IL) 23/IL-17A axis has had a major impact on the quality of life for many patients with AS, and one…

    Research in Temporal Arteritis Suggests Link with Infection, Autoimmune Disease

    November 16, 2015

    Temporal arteritis was first described by Sir Jonathan Hutchinson in 1890 in an elderly retired gentleman’s servant who developed red, painful streaks on his temples and was found to have bilaterally swollen temporal arteries with feeble pulses.1 Sir Hutchinson disputed the suggestion that the red streaks were caused by the man’s hat and, instead, called…

    Meet the HEP C Challenge

    December 1, 2008

    Keep a hepatitis C virus infection from hindering RA treatment

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences